Skip to main content

Drug Interactions between Qulipta and Ubrelvy

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Qulipta and Ubrelvy. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Qulipta

A total of 208 drugs are known to interact with Qulipta.

Ubrelvy

A total of 249 drugs are known to interact with Ubrelvy.

Drug and food/lifestyle interactions

Moderate

ubrogepant food/lifestyle

Applies to: Ubrelvy (ubrogepant)

Grapefruit and grapefruit juice can increase the blood levels of ubrogepant. This may increase side effects such as nausea and sleepiness. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe an alternative that does not interact, or you may need a different dose to safely use your medication with grapefruit and grapefruit juice. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

atogepant food/lifestyle

Applies to: Qulipta (atogepant)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with grapefruit products or green tea, inhibitors of CYP450 3A4, may increase the plasma concentrations of atogepant, which is primarily metabolized by the isoenzyme. When atogepant was administered with the potent CYP450 3A4 inhibitor itraconazole in healthy study subjects, atogepant peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.2- and 5.5-fold, respectively. However, moderate and weak inhibitors may interact to a much lesser extent. Population pharmacokinetic modeling has suggested that moderate (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) or weak (e.g., cimetidine, esomeprazole) CYP450 3A4 inhibitors may increase atogepant AUC by 1.7- and 1.1-fold, respectively. The changes in atogepant exposure when coadministered with moderate or weak CYP450 3A4 inhibitors are not expected to be clinically significant.

MANAGEMENT: Caution is advised for patients taking atogepant and consuming grapefruit products, large amounts of green tea beverages or green tea extract. Patients should be monitored for nausea, constipation, and fatigue.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Cgrp inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'CGRP inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'CGRP inhibitors' category:

  • Qulipta (atogepant)
  • Ubrelvy (ubrogepant)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.